Base de dados : MEDLINE
Pesquisa : C04.557.386.480.350 [Categoria DeCS]
Referências encontradas : 4978 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 498 ir para página                         

  1 / 4978 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29318369
[Au] Autor:Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova M; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
[Ad] Endereço:Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic. janikova.andrea@fnbrno.cz.
[Ti] Título:The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
[So] Source:Ann Hematol;97(4):669-678, 2018 Apr.
[Is] ISSN:1432-0584
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The aim of this study is to assess the incidence, risk factors, and outcome of biopsy-proven transformation in follicular lymphoma (FL) patients in the rituximab era. Transformation was analyzed in 1233 patients with initially diagnosed FL grades 1-3A, identified between 2002 and 2012 in the prospectively maintained Czech Lymphoma Study Group database. Only patients with histologically proven transformation (HT) were included. HT occurred in 58 cases at a median of 3.0 years from the initial FL diagnosis; the HT rate was 4% at 5 years. Transformation occurred most frequently at the first relapse (84% patients). Median OS from the HT was 2.5 years (95% CI 0.4-4.6) and 6-year OS with HT was shorter compared to all FLs (60 vs. 83.9%; 95% CI). A bulky tumor (≥ 10 cm), increased lactate dehydrogenase, age ≥ 60 years, and International Prognostic Index (intermediate/high risk), but not Follicular Lymphoma International Prognostic Index, were associated with transformation (p < 0.05). In the first line, 70% of patients received rituximab (including 36% rituximab maintenance), 57% CHOP-like regimens, and 2.6% of patients were treated with fludarabine-based therapy, whereas 11% of patients were watched only. The patients treated with R-CHOP in the first line (n = 591) showed the transformation rate at 5 years of 4.23% (95% CI 2.52-5.93); subsequent rituximab maintenance (n = 276) vs. observation (n = 153) was associated with a lower transformation rate (p.033; HR 3.29; CI 1.10-9.82). The transformation rate seems to be lower than in previous series, which may be influenced by broad use of rituximab, but prognosis of HT developed during therapy continues to be poor.
[Mh] Termos MeSH primário: Antineoplásicos Imunológicos/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Transformação Celular Neoplásica/efeitos dos fármacos
Linfoma Folicular/tratamento farmacológico
Rituximab/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Antraciclinas/efeitos adversos
Antraciclinas/uso terapêutico
Antineoplásicos Imunológicos/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Biópsia
Transformação Celular Neoplásica/patologia
Estudos de Coortes
República Tcheca/epidemiologia
Feminino
Seguimentos
Seres Humanos
Incidência
Linfoma Folicular/epidemiologia
Linfoma Folicular/patologia
Linfoma Folicular/prevenção & controle
Quimioterapia de Manutenção/efeitos adversos
Masculino
Meia-Idade
Sistema de Registros
Estudos Retrospectivos
Rituximab/efeitos adversos
Prevenção Secundária
Análise de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anthracyclines); 0 (Antineoplastic Agents, Immunological); 4F4X42SYQ6 (Rituximab)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE
[do] DOI:10.1007/s00277-017-3218-0


  2 / 4978 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29230799
[Au] Autor:Solal-Céligny P; Leconte P; Bardet A; Hernandez J; Troussard X
[Ad] Endereço:Institut de Cancérologie de l'Ouest, Saint Herblain, France.
[Ti] Título:A retrospective study on the management of patients with rituximab refractory follicular lymphoma.
[So] Source:Br J Haematol;180(2):217-223, 2018 01.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Given that there are currently no clear recommendations regarding therapeutic options for rituximab refractory/relapsed follicular lymphoma patients, this study aimed to describe the real-life management of patients with refractory follicular lymphoma after systemic rituximab-containing regimens (rFL), and rFL patient characteristics. In this retrospective, national, multicentre study, descriptive analyses were mainly performed according to rituximab-containing regimen at rFL diagnosis [rituximab monotherapy (R-MONO), rituximab + chemotherapy (R-COMBO), and ongoing rituximab maintenance (R-MAINTAIN)]. The 459 analysed patients experienced rituximab-refractoriness between October 2013 and September 2015: R-MONO: 58 (13%), R-COMBO: 197 (43%), R-MAINTAIN: 204 (44%). Post-refractoriness strategies were heterogeneous: idelalisib ± rituximab (22%), without anti-lymphoma treatment (21%), rituximab-chemotherapy (21%) and stem cell transplantation (18%). Rituximab was continued in combination in 41% of cases. Chosen strategies varied according to patient age (without anti-lymphoma treatment: 28% of patients if ≥65 years vs. 12% if <65 years old; stem-cell transplantation: 4% vs. 38%), treatment line at rFL, FL International Prognostic Index score and prior treatment. This French retrospective study, the first one conducted in a large cohort of rFL patients, showed that further strategies were highly heterogeneous, depending notably on patient characteristics and previous treatment. These data are the basis for a better understanding of rFL management and for the design of clinical trials in these patients.
[Mh] Termos MeSH primário: Linfoma Folicular/terapia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Antineoplásicos Imunológicos/administração & dosagem
Antineoplásicos Imunológicos/efeitos adversos
Antineoplásicos Imunológicos/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Tomada de Decisão Clínica
Terapia Combinada
Comorbidade
Gerenciamento Clínico
Resistência a Medicamentos Antineoplásicos
Feminino
Seres Humanos
Linfoma Folicular/diagnóstico
Linfoma Folicular/mortalidade
Masculino
Meia-Idade
Estadiamento de Neoplasias
Retratamento
Estudos Retrospectivos
Rituximab/administração & dosagem
Rituximab/efeitos adversos
Rituximab/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents, Immunological); 4F4X42SYQ6 (Rituximab)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.15023


  3 / 4978 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29193015
[Au] Autor:Zamò A; Pischimarov J; Horn H; Ott G; Rosenwald A; Leich E
[Ad] Endereço:Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
[Ti] Título:The exomic landscape of t(14;18)-negative diffuse follicular lymphoma with 1p36 deletion.
[So] Source:Br J Haematol;180(3):391-394, 2018 02.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Predominantly diffuse t(14;18) negative follicular lymphoma (FL) with 1p36 deletion shows distinctive clinical, morphological and molecular features that distinguish it from classical FL. In order to investigate whether it possesses a unique mutation profile, we performed whole exome sequencing of six well-characterised cases. Our analysis showed that the mutational landscape of this subtype is largely distinct from classical FL. It appears to harbour several recurrent mutations, affecting STAT6, CREBBP and basal membrane protein genes with high frequency. Our data support the view that this FL subtype should be considered a separate entity from classical FL.
[Mh] Termos MeSH primário: Deleção Cromossômica
Cromossomos Humanos Par 1
Exoma
Predisposição Genética para Doença
Linfoma Folicular/genética
Linfoma Folicular/patologia
Translocação Genética
[Mh] Termos MeSH secundário: Cromossomos Humanos Par 14
Cromossomos Humanos Par 18
Seres Humanos
Mutação
Polimorfismo de Nucleotídeo Único
Sequenciamento Completo do Exoma
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.15041


  4 / 4978 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29381956
[Au] Autor:Péricart S; Martin-Blondel G; Franchet C; Hitzel A; Brousset P
[Ad] Endereço:Departement de Pathologie, Institut Universitaire du Cancer Oncopole de Toulouse.
[Ti] Título:18F-Fluorodeoxyglucose positron emission tomography computed tomography detection threshold in follicular lymphoma: A case report.
[So] Source:Medicine (Baltimore);96(47):e8705, 2017 Nov.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Follicular Lymphoma in situ is generally identified as reactive follicular hyperplasia in which some of the hyperplastic germinal centers are colonized by few lymphoma cells. These cells can be detected through their strong 18F-Fluorodeoxyglucose avidity. PATIENT CONCERNS: We report the case of a 70 year-old patient with arthralgia, weight loss and chronic fever over two months. A paraneoplastic polymyalgia rheumatica was initially suspected on abnormal 18F fluoro-deoxyglucose positron emission tomography (PET) pictures in two inguinal lymph nodes with a standardized uptake value at 8.6 and 5.8. DIAGNOSES: The PET lymph nodes were removed and histological examination revealed subtle lymph nodes infiltration by follicular lymphoma in situ. The absolute number of the follicular lymphoma cells determined using virtual imaging and 3D reconstruction appeared very low with a total tumor cell volume estimated at around 0.026 mm for one lymph node and 0.041 mm for the other. INTERVENTIONS: The patient has been treated by corticotherapy alone. OUTCOMES: A long-time follow-up should be highly suggested for this patient to avoid any risk of clinical progression to follicular lymphoma. LESSONS: Our findings show that low amounts of follicular lymphoma cells in reactive germinal center may reach a threshold of hypermetabolism detectable with positron emission tomography imaging, suggesting that tumor microenvironment also accounts for such as strong fluoro-deoxyglucose avidity. Thus, a systematic immunohistochemistry with anti-BCL2 antibodies should be performed on PET positive lymph node with apparent normal morphological features.
[Mh] Termos MeSH primário: Linfoma Folicular/diagnóstico por imagem
Linfoma Folicular/patologia
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons/métodos
[Mh] Termos MeSH secundário: Corticosteroides/uso terapêutico
Idoso
Diagnóstico Diferencial
Fluordesoxiglucose F18
Centro Germinativo/patologia
Seres Humanos
Linfoma Folicular/tratamento farmacológico
Masculino
Compostos Radiofarmacêuticos
Sensibilidade e Especificidade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Radiopharmaceuticals); 0Z5B2CJX4D (Fluorodeoxyglucose F18)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008705


  5 / 4978 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28466570
[Au] Autor:Boyle T; Connors JM; Gascoyne RD; Berry BR; Sehn LH; Bashash M; Spinelli JJ
[Ad] Endereço:School of Public Health, Curtin University, Perth, WA, Australia.
[Ti] Título:Physical activity, obesity and survival in diffuse large B-cell and follicular lymphoma cases.
[So] Source:Br J Haematol;178(3):442-447, 2017 08.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:There is limited information concerning the impact of physical activity and obesity on non-Hodgkin lymphoma (NHL) prognosis. We examined the associations between pre-diagnosis physical activity and body mass index (BMI) with survival in 238 diffuse large B-cell (DLBCL) and 175 follicular lymphoma cases, with follow-up from 2000 to 2015. The most physically active DLBCL cases had 41% lower risk of dying in the follow-up period than the least active [Hazard ratio (HR) = 0·59, 95% confidence interval (CI) = 0·36-0·96], while obese follicular lymphoma cases had a 2·5-fold risk of dying (HR = 2·52, 95% CI = 1·27-5·00) compared with cases with normal BMI. NHL-specific survival results were similar.
[Mh] Termos MeSH primário: Exercício/fisiologia
Linfoma Folicular/complicações
Linfoma Difuso de Grandes Células B/complicações
Obesidade/complicações
[Mh] Termos MeSH secundário: Adulto
Idoso
Antineoplásicos/uso terapêutico
Índice de Massa Corporal
Colúmbia Britânica/epidemiologia
Estudos de Casos e Controles
Feminino
Seguimentos
Seres Humanos
Estimativa de Kaplan-Meier
Estilo de Vida
Linfoma Folicular/tratamento farmacológico
Linfoma Folicular/mortalidade
Linfoma Folicular/fisiopatologia
Linfoma Difuso de Grandes Células B/tratamento farmacológico
Linfoma Difuso de Grandes Células B/mortalidade
Linfoma Difuso de Grandes Células B/fisiopatologia
Masculino
Meia-Idade
Obesidade/mortalidade
Obesidade/fisiopatologia
Prognóstico
Rituximab/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 4F4X42SYQ6 (Rituximab)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.14702


  6 / 4978 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28466487
[Au] Autor:Epperla N; Pham AQ; Burnette BL; Wiseman GA; Habermann TM; Macon WR; Ansell SM; Inwards DJ; Micallef IN; Johnston PB; Markovic SN; Porrata LF; Colgan JP; Ristow KM; Nowakowski GS; Witzig TE
[Ad] Endereço:Department of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
[Ti] Título:Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
[So] Source:Br J Haematol;178(3):427-433, 2017 08.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Histological transformation (HT) of follicular lymphoma (FL) to an aggressive lymphoma after chemotherapy remains a key issue. The incidence of HT after radioimmunotherapy (RIT) is unknown. This single institution study analysed the risk of HT in FL after treatment with yttrium-90 ibritumomab tiuxetan in 115 consecutive patients treated during 1987-2012. RIT was administered for progressive FL in 111 (97%) patients and as first-line therapy in the remaining 4. 28% (n = 32) had HT, occurring at a median of 60 months from diagnosis and 20 months after RIT. 48% (12/25) of patients who received fludarabine developed HT. The estimated 10-year risk of HT in the fludarabine and non-fludarabine groups was 67% and 26% respectively (P = 0·015). Only prior fludarabine was significantly associated with predicting the risk of HT after RIT. 8% (9/115) of patients developed therapy-related myelodysplastic syndrome/acute myeloid leukaemia (tMDS/AML) at a median of 41·4 months (range, 5-89). The estimated 10-year risk of tMDS/AML in non-fludarabine treated patients (n = 90) versus fludarabine treated (n = 25) was 13% and 29%, respectively. The estimated overall risk of FL undergoing HT at 10 years without fludarabine exposure appears similar to patients reported in the literature that have not received RIT. Patients with prior purine-analogue therapy are at significantly higher risk of HT.
[Mh] Termos MeSH primário: Leucemia Mieloide Aguda/etiologia
Linfoma Folicular/terapia
Síndromes Mielodisplásicas/etiologia
Segunda Neoplasia Primária/etiologia
Radioimunoterapia/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Anticorpos Monoclonais/efeitos adversos
Anticorpos Monoclonais/uso terapêutico
Quimioterapia Adjuvante/efeitos adversos
Bases de Dados Factuais
Feminino
Seres Humanos
Masculino
Meia-Idade
Neoplasias Induzidas por Radiação/etiologia
Radioimunoterapia/métodos
Fatores de Risco
Rituximab/efeitos adversos
Rituximab/uso terapêutico
Vidarabina/efeitos adversos
Vidarabina/análogos & derivados
Vidarabina/uso terapêutico
Adulto Jovem
Radioisótopos de Ítrio/efeitos adversos
Radioisótopos de Ítrio/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Yttrium Radioisotopes); 4F4X42SYQ6 (Rituximab); 4Q52C550XK (ibritumomab tiuxetan); FA2DM6879K (Vidarabine); P2K93U8740 (fludarabine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.14688


  7 / 4978 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Registro de Ensaios Clínicos
Texto completo
[PMID]:29226764
[Au] Autor:Schuster SJ; Svoboda J; Chong EA; Nasta SD; Mato AR; Anak Ö; Brogdon JL; Pruteanu-Malinici I; Bhoj V; Landsburg D; Wasik M; Levine BL; Lacey SF; Melenhorst JJ; Porter DL; June CH
[Ad] Endereço:From the Lymphoma Program at the Abramson Cancer Center and the Division of Hematology-Oncology (S.J.S., J.S., E.A.C., S.D.N., A.R.M., D.L., D.L.P.), and the Department of Pathology and Laboratory Medicine (V.B., M.W., B.L.L., S.F.L., J.J.M., C.H.J.), Perelman School of Medicine, University of Penns
[Ti] Título:Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
[So] Source:N Engl J Med;377(26):2545-2554, 2017 12 28.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Patients with diffuse large B-cell lymphoma or follicular lymphoma that is refractory to or that relapses after immunochemotherapy and transplantation have a poor prognosis. High response rates have been reported with the use of T cells modified by chimeric antigen receptor (CAR) that target CD19 in B-cell cancers, although data regarding B-cell lymphomas are limited. METHODS: We used autologous T cells that express a CD19-directed CAR (CTL019) to treat patients with diffuse large B-cell lymphoma or follicular lymphoma that had relapsed or was refractory to previous treatments. Patients were monitored for response to treatment, toxic effects, the expansion and persistence of CTL019 cells in vivo, and immune recovery. RESULTS: A total of 28 adult patients with lymphoma received CTL019 cells, and 18 of 28 had a response (64%; 95% confidence interval [CI], 44 to 81). Complete remission occurred in 6 of 14 patients with diffuse large B-cell lymphoma (43%; 95% CI, 18 to 71) and 10 of 14 patients with follicular lymphoma (71%; 95% CI, 42 to 92). CTL019 cells proliferated in vivo and were detectable in the blood and bone marrow of patients who had a response and patients who did not have a response. Sustained remissions were achieved, and at a median follow-up of 28.6 months, 86% of patients with diffuse large B-cell lymphoma who had a response (95% CI, 33 to 98) and 89% of patients with follicular lymphoma who had a response (95% CI, 43 to 98) had maintained the response. Severe cytokine-release syndrome occurred in 5 patients (18%). Serious encephalopathy occurred in 3 patients (11%); 2 cases were self-limiting and 1 case was fatal. All patients in complete remission by 6 months remained in remission at 7.7 to 37.9 months (median, 29.3 months) after induction, with a sustained reappearance of B cells in 8 of 16 patients and with improvement in levels of IgG in 4 of 10 patients and of IgM in 6 of 10 patients at 6 months or later and in levels of IgA in 3 of 10 patients at 18 months or later. CONCLUSIONS: CTL019 cells can be effective in the treatment of relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma. High rates of durable remission were observed, with recovery of B cells and immunoglobulins in some patients. Transient encephalopathy developed in approximately one in three patients and severe cytokine-release syndrome developed in one in five patients. (Funded by Novartis and others; ClinicalTrials.gov number, NCT02030834 .).
[Mh] Termos MeSH primário: Imunoterapia Adotiva
Linfoma Folicular/terapia
Linfoma Difuso de Grandes Células B/terapia
Receptores de Antígenos de Linfócitos T/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Antígenos CD19
Linfócitos B/imunologia
Biomarcadores/análise
Intervalo Livre de Doença
Feminino
Seres Humanos
Linfoma Folicular/mortalidade
Linfoma Difuso de Grandes Células B/mortalidade
Masculino
Meia-Idade
Indução de Remissão
Análise de Sobrevida
Linfócitos T/imunologia
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antigens, CD19); 0 (Biomarkers); 0 (CTL019 chimeric antigen receptor); 0 (Receptors, Antigen, T-Cell)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171212
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMoa1708566


  8 / 4978 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29281573
[Au] Autor:Nair R; Tabchi S; Hagemeister F
[Ad] Endereço:University of Texas M.D. Anderson Cancer Center, Houston, TX ranjitnair999@gmail.com.
[Ti] Título:Obinutuzumab Treatment of Follicular Lymphoma.
[So] Source:N Engl J Med;377(26):2605, 2017 12 28.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados
Linfoma Folicular
[Mh] Termos MeSH secundário: Seres Humanos
Rituximab
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); 4F4X42SYQ6 (Rituximab); O43472U9X8 (obinutuzumab)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171228
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1714337


  9 / 4978 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29281572
[Au] Autor:Marcus R; Seymour JF; Hiddemann W
[Ad] Endereço:King's College Hospital, London, United Kingdom marcus.re@googlemail.com
[Ti] Título:Obinutuzumab Treatment of Follicular Lymphoma.
[So] Source:N Engl J Med;377(26):2605-2606, 2017 12 28.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados
Linfoma Folicular
[Mh] Termos MeSH secundário: Seres Humanos
Rituximab
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); 4F4X42SYQ6 (Rituximab); O43472U9X8 (obinutuzumab)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171228
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1714337


  10 / 4978 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29173973
[Au] Autor:Gauthier J; Chantepie S; Bouabdallah K; Jost E; Nguyen S; Gac AC; Damaj G; Duléry R; Michallet M; Delage J; Lewalle P; Morschhauser F; Salles G; Yakoub-Agha I; Cornillon J
[Ad] Endereço:CHRU de Lille, pôle spécialités médicales et gérontologie, service des maladies du sang, secteur allogreffe de cellules souches hématopoïétiques, 59037 Lille, France; Université de Lille, UFR médecine, 59000 Lille, France.
[Ti] Título:[Allogeneic haematopoietic cell transplantation for indolent lymphomas: Guidelines from the Francophone Society Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
[Ti] Título:Allogreffe de cellules souches hématopoïétiques dans les lymphomes indolents : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)..
[So] Source:Bull Cancer;104(12S):S121-S130, 2017 Dec.
[Is] ISSN:1769-6917
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic hematopoietic cell transplantation is a potentially curative option, this is true particularly the case of relapse after autologous stem cell transplantation. Recently, novel agents such as anti-PD1 and BTK inhibitors have started to challenge the use of allogeneic hematopoietic cell transplantation for relapsed or refractory lymphoma. During the 2016 annual workshop of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), we performed a comprehensive review of the literature published in the last 10 years and established guidelines to clarify the indications and transplant modalities in this setting. This paper specifically reports on our conclusions regarding indolent lymphomas, mainly follicular lymphoma and chronic lymphocytic leukemia.
[Mh] Termos MeSH primário: Transplante de Células-Tronco Hematopoéticas/normas
Leucemia Linfocítica Crônica de Células B/terapia
Linfoma Folicular/terapia
Linfoma de Célula do Manto/terapia
Macroglobulinemia de Waldenstrom/terapia
[Mh] Termos MeSH secundário: Algoritmos
Aloenxertos
Tomada de Decisões
França
Seres Humanos
Recidiva
Sociedades Médicas
[Pt] Tipo de publicação:CONSENSUS DEVELOPMENT CONFERENCE; JOURNAL ARTICLE; PRACTICE GUIDELINE; REVIEW
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171228
[Lr] Data última revisão:
171228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE



página 1 de 498 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde